Nasdaq · Healthcare

Caribou Biosciences, Inc. (CRBU)

As-reported financials and recent SEC filings for Caribou Biosciences, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$11.2M

Net income

$-148.1M

Net margin

—

Diluted EPS

$-1.59

ROE

-121.2%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$11.2M	$10.0M	$34.5M	$13.9M	$9.6M
Gross profit	—	—	—	—	—
Operating income	$-148.3M	$-166.6M	$-116.1M	$-106.4M	$-67.0M
Net income	$-148.1M	$-149.1M	$-102.1M	$-99.4M	$-66.9M
Diluted EPS	$-1.59	$-1.65	$-1.38	$-1.64	$-1.05

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

8-K2026-06-18

8-K2026-06-11

DEFA14A2026-06-05

10-Q2026-05-07

8-K2026-05-07

DEFR14A2026-05-01

ARS2026-04-24

DEFA14A2026-04-24

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on CRBU

Search Caribou Biosciences, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.